Curi Bio and Novoheart Collaboration Enhances Cardiac Research
Curi Bio, a leader in providing human functional data for drug discovery, has announced an exciting venture with Novoheart, a pioneer in human cardiac tissue engineering. This integration focuses on the MyHeart™ human ventricular cardiac organoid chamber (hvCoC) platform, thereupon referred to as the "Human Heart-in-a-Jar." This technology is now integrated into Curi Bio's advanced Pulse™ analysis platform, allowing biopharmaceutical researchers to gain deeper insights into drug development and disease modeling.
The MyHeart™ Technology Explained
One of the key advancements introduced by Novoheart is the MyHeart™ hvCoC, which stands unmatched in the industry due to its capacity for delivering clinically informative assessments of human heart performance. This superior technology melds with custom-designed hardware and software to create the best-in-class model that supports drug screening and disease modeling. Consequently, it allows researchers to analyze how new drugs impact vital cardiac parameters such as pressure, stroke area, stroke work, and ejection fraction.
Curi Bio’s Revolutionary Pulse Platform
Curi Bio’s Pulse platform merges sophisticated machine learning techniques with high-throughput data analysis and user-friendly visualization tools. This synergy streamlines functional analyses of intricate biological datasets derived from both 3D and 2D models, offering scientists a straightforward process for data interpretation. Curi Bio's flagship products, Mantarray™ and Nautilai™, seamlessly utilize Pulse to enhance workflows, providing researchers with human-relevant data at every stage.
Introducing Enhanced Capabilities for Researchers
The remarkable collaboration between Curi Bio and Novoheart expands the predictive capabilities of the hvCoC platform through advanced software analytics. This consolidation empowers cardiac scientists to accelerate preclinical validation processes while reducing costs associated with drug development. The functions of contractility can now be quantitatively measured more efficiently, enhancing the prospects for new cardiac therapies.
Thoughts from the Leadership
Dr. Kevin Costa, Co-founder and Chief Scientific Officer at Novoheart, expressed enthusiasm over this integration: "Our hvCoC provides the most sophisticated in vitro model of human heart function, and through this partnership with Curi Bio, our customers will benefit from powerful and user-friendly analytics. It enhances researchers' abilities to extract meaningful insights quickly, supporting the development of safer cardiac therapies."
Commitment to Drug Discovery
Echoing Dr. Costa's sentiment, Dr. Nicholas A. Geisse, CEO at Curi Bio, emphasized the significance of this collaboration: "This initiative represents our steadfast dedication to innovative human-relevant drug discovery solutions. By joining forces with Novoheart, we are committed to advancing the forefront of human cardiac technologies, with the ultimate goal of benefiting patients everywhere."
About Curi Bio
Curi Bio is at the cutting edge of biopharmaceutical research and development, providing innovative workflows and functional human data to drive informed decision-making. With advanced 3D tissue models and analytical insights powered by AI/ML technology, Curi Bio is reshaping how drug safety, efficacy, and potency are assessed. The company's preclinical platforms generate clinically-relevant data, effectively connecting preclinical research with clinical outcomes.
About Novoheart
Recognized globally, Novoheart is pioneering the field of human cardiac tissue models, shaping the future of drug discovery. Its innovative mini-Heart Platform, which includes the hvCoC, offers invaluable insights into cardiac research and therapeutic development. Novoheart's commitment is to create human-specific alternatives to animal testing and to fast-track the development of safer, more effective therapies.
Frequently Asked Questions
What is the focus of the collaboration between Curi Bio and Novoheart?
The partnership is centered around integrating Novoheart's MyHeart™ hvCoC platform into Curi Bio's Pulse analytics system for enhanced cardiac research.
How does the MyHeart™ hvCoC technology contribute to drug discovery?
This technology enables researchers to assess human cardiac performance accurately and efficiently, providing insights into how new drugs may perform.
What role does Curi Bio’s Pulse platform play in this collaboration?
The Pulse platform allows for high-throughput data analysis and visualization, fostering a seamless workflow for scientists working with complex biological datasets.
Who expressed excitement about the integration?
Dr. Kevin Costa, Co-founder and Chief Scientific Officer of Novoheart, highlighted the benefits for researchers from this integration.
Why is this collaboration considered important?
It exemplifies the commitment to advancing human-specific cardiac technologies, ultimately enhancing therapeutic development and patient care.
